Angela M. Davies
About
Angela M. Davies is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Angela M. Davies has authored 121 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 44 papers in Molecular Biology. Recurrent topics in Angela M. Davies's work include Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Research Studies (31 papers) and Colorectal Cancer Treatments and Studies (19 papers). Angela M. Davies is often cited by papers focused on Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Research Studies (31 papers) and Colorectal Cancer Treatments and Studies (19 papers). Angela M. Davies collaborates with scholars based in United States, Canada and United Kingdom. Angela M. Davies's co-authors include David R. Gandara, Primo N. Lara, Philip C. Mack, Ning Qiao, Walkiria Schlindwein, Mingzhong Li, Paul H. Gumerlock, Uri Weinberg, Yoram Palti and Derick Lau and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
In The Last Decade
Angela M. Davies
118 papers receiving 3.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Angela M. Davies United States | 31 | 1.6k | 1.3k | 960 | 514 | 458 | 121 | 3.5k | ||
| Richard J. Jones United States | 30 | 821 0.5× | 283 0.2× | 1.2k 1.2× | 236 0.5× | 127 0.3× | 116 | 4.1k | ||
| Satoshi Nagayama Japan | 52 | 2.7k 1.7× | 1.3k 1.0× | 2.0k 2.1× | 488 0.9× | 48 0.1× | 250 | 8.2k | ||
| Christian A. Thomas United States | 22 | 5.3k 3.3× | 2.6k 1.9× | 2.1k 2.1× | 287 0.6× | 33 0.1× | 58 | 7.9k | ||
| Sung Hee Lim South Korea | 31 | 1.1k 0.7× | 853 0.6× | 855 0.9× | 270 0.5× | 16 0.0× | 119 | 3.5k | ||
| J. Denekamp United Kingdom | 52 | 1.7k 1.1× | 2.6k 2.0× | 2.7k 2.8× | 156 0.3× | 49 0.1× | 206 | 9.0k | ||
| S. Percy Ivy United States | 43 | 3.6k 2.3× | 1.3k 1.0× | 4.1k 4.3× | 145 0.3× | 106 0.2× | 189 | 7.9k | ||
| Jorge J. Nieva United States | 35 | 1.6k 1.0× | 850 0.6× | 1.2k 1.2× | 69 0.1× | 27 0.1× | 163 | 4.3k | ||
| Hiroshi Kawabata Japan | 34 | 880 0.6× | 293 0.2× | 1.3k 1.4× | 523 1.0× | 116 0.3× | 241 | 5.7k | ||
| Percy Ivy United States | 36 | 1.5k 0.9× | 883 0.7× | 1.9k 2.0× | 83 0.2× | 41 0.1× | 120 | 4.5k | ||
| M. E. Scheulen Germany | 36 | 2.6k 1.6× | 1.2k 0.9× | 2.3k 2.4× | 96 0.2× | 11 0.0× | 178 | 5.5k |
Countries citing papers authored by Angela M. Davies
Since
Specialization
Citations
This map shows the geographic impact of Angela M. Davies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela M. Davies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela M. Davies more than expected).
Fields of papers citing papers by Angela M. Davies
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Angela M. Davies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela M. Davies. The network helps show where Angela M. Davies may publish in the future.
Co-authorship network of co-authors of Angela M. Davies
This figure shows the co-authorship network connecting the top 25 collaborators of Angela M. Davies. A scholar is included among the top collaborators of Angela M. Davies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela M. Davies. Angela M. Davies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Davies, Angela M., Manuel Hidalgo, Justin Stebbing, et al.. (2016). Mouse clinical trials of pancreatic cancer: Integration of PDX models with genomics to improve patient outcomes to chemotherapeutics. Annals of Oncology. 27. vi527–vi527.
2.
Ho, Cheryl, Angela M. Davies, Randeep Sangha, et al.. (2013). Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Investigational New Drugs. 31(6). 1587–1591.
3.
Lau, Derick, James Moon, Angela M. Davies, et al.. (2013). Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced Adenocarcinoma. Clinical Lung Cancer. 14(4). 351–355.
4.
Camidge, D. Ross, Scott A. Kono, Xian Lu, et al.. (2011). Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed. Journal of Thoracic Oncology. 6(4). 774–780.
5.
Chew, Helen K., George Somlo, Philip C. Mack, et al.. (2011). Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Annals of Oncology. 23(4). 1023–1029.
6.
Gitlitz, Barbara J., Denice Tsao‐Wei, Susan Groshen, et al.. (2011). A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial. Journal of Thoracic Oncology. 7(3). 574–578.
7.
Davies, Angela M., Kari Chansky, Primo N. Lara, et al.. (2009). Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339). Journal of Thoracic Oncology. 4(1). 87–92.
8.
Davies, Angela M., Cheryl Ho, Laurel Beckett, et al.. (2009). Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation. Journal of Thoracic Oncology. 4(7). 862–868.
9.
Mack, Philip C., William Holland, Rebekah A. Burich, et al.. (2009). EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(12). 1466–1472.
10.
Gautschi, Oliver, Philip C. Mack, Angela M. Davies, et al.. (2008). Pharmacogenomic Approaches to Individualizing Chemotherapy for Non–Small-Cell Lung Cancer: Current Status and New Directions. Clinical Lung Cancer. 9. S129–S138.
11.
Sanders, Eduard J., Simon Graham, Haile Selassie Okuku, et al.. (2007). Risk factors for HIV-1 infection and high HIV-1 incidence of men who have sex with men, in and around Mombasa, Kenya. Tropical Medicine & International Health. 12. 88–88.
12.
Herbst, Roy S., Angela M. Davies, Ronald B. Natale, et al.. (2007). Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 13(20). 6175–6181.
13.
Davies, Angela M., Cheryl Ho, Laurel Beckett, et al.. (2007). Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(12). 1112–1116.
14.
Davies, Angela M., Raja Mudad, James Moon, et al.. (2007). PD3-1-7: Phase II trial of autologous cancer vaccine, CG8123 (GVAX), in patients with advanced bronchioloalveolar carcinoma (BAC): a Southwest Oncology Group Study (S0310).. Journal of Thoracic Oncology. 2(8). S461–S461.
15.
Gautschi, Oliver, Philip C. Mack, Angela M. Davies, Primo N. Lara, & David R. Gandara. (2006). Aurora Kinase Inhibitors: A New Class of Targeted Drugs in Cancer. Clinical Lung Cancer. 8(2). 93–98.
16.
Lara, Primo N., Kari Chansky, Angela M. Davies, et al.. (2006). Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327). Journal of Thoracic Oncology. 1(9). 996–1001.
17.
Davies, Angela M., Kari Chansky, Derick Lau, et al.. (2006). Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712. Journal of Clinical Oncology. 24(33). 5242–5246.
18.
Lara, Primo N., David I. Quinn, Heinz Josef Lenz, et al.. (2006). Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. Journal of Thoracic Oncology. 1(2). 126–134.
19.
Davies, Angela M., David R. Gandara, Primo N. Lara, et al.. (2002). Current and future therapeutic approaches in locally advanced (stage III) non[ndash ]small cell lung cancer. Seminars in Oncology. 29(3 Suppl 12). 10–16.
20.
Davies, Angela M.. (1995). Manipulation and orientation of soft products with controlled air jets using distributed microcontroller based fuzzy logic control. 1995. 2–2.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Richard J. Jones Breakdown of academic impact, for papers by Satoshi Nagayama Breakdown of academic impact, for papers by Christian A. Thomas Breakdown of academic impact, for papers by Sung Hee Lim Breakdown of academic impact, for papers by J. Denekamp Breakdown of academic impact, for papers by S. Percy Ivy Breakdown of academic impact, for papers by Jorge J. Nieva Breakdown of academic impact, for papers by Hiroshi Kawabata Breakdown of academic impact, for papers by Percy Ivy Breakdown of academic impact, for papers by M. E. Scheulen